Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Inclusion Criteria:

1. Subjects fully understand this study, are able to follow the relevant procedures ofthe trial, voluntarily participate in the clinical trial, and sign the informedconsent form (ICF);

2. The age requirement for signing the ICF is 18 years old or above, with no genderrestrictions;

3. During screening, the diagnosis of atopic dermatitis should be met according to theHanifin-Rajka criteria;

Exclusion Criteria:

1. Skin damage or abnormalities that may affect the evaluation of the administrationsite of the investigational drug;

2. Skin diseases that are contraindicated in research or affect the evaluation of drugadministration sites, including but not limited to psoriasis, acne, and skin cancer;

3. Suffering from autoimmune diseases other than AD, such as inflammatory bowel diseaseand rheumatoid arthritis, and the researchers believe that this disease will bedetrimental to the evaluation of this study;

4. Current history of or presence of lymphoproliferative disorders, or signs orsymptoms suggesting possible lymphoproliferative disorders, includinglymphadenopathy or splenomegaly;

5. Various malignant tumors, or any history of malignant tumors within the past 5 yearsprior to screening (excluding completely resected cervical carcinoma in situ, nonmetastatic squamous cell carcinoma, basal cell carcinoma, or papillary thyroidcarcinoma);